227 related articles for article (PubMed ID: 31741764)
1. Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis.
El-Osta HE; Mott FE; Burt BM; Wang DY; Sabichi AL
Oncoimmunology; 2019; 8(12):e1665974. PubMed ID: 31741764
[No Abstract] [Full Text] [Related]
2. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
4. Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
Liu T; Wu S; Fang W; Li H; Su L; Qi G; Li H; Liu Y
PLoS One; 2023; 18(4):e0283719. PubMed ID: 37071610
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
Sheng L; Gao J; Xu Q; Zhang X; Huang M; Dai X; Li S; Liu L
Ther Adv Med Oncol; 2021; 13():17588359211018537. PubMed ID: 34104227
[TBL] [Abstract][Full Text] [Related]
8. A Network Meta-Analysis of Cancer Immunotherapies
Herbst R; Jassem J; Abogunrin S; James D; McCool R; Belleli R; Giaccone G; De Marinis F
Front Oncol; 2021; 11():676732. PubMed ID: 34307144
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
Siciliano MA; Caridà G; Ciliberto D; d'Apolito M; Pelaia C; Caracciolo D; Riillo C; Correale P; Galvano A; Russo A; Barbieri V; Tassone P; Tagliaferri P
ESMO Open; 2022 Jun; 7(3):100465. PubMed ID: 35427835
[TBL] [Abstract][Full Text] [Related]
11. First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Tanimura K; Takeda T; Kataoka N; Yoshimura A; Nakanishi K; Yamanaka Y; Yoshioka H; Honda R; Uryu K; Fukui M; Chihara Y; Takei S; Kawachi H; Yamada T; Tamiya N; Okura N; Yamada T; Murai J; Shiotsu S; Kurata T; Takayama K
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894357
[TBL] [Abstract][Full Text] [Related]
12. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
Pang LL; Gan JD; Huang YH; Liao J; Zhuang WT; Ali WA; Hong SD; Zhang L; Fang WF
BMC Cancer; 2023 Jan; 23(1):72. PubMed ID: 36670414
[TBL] [Abstract][Full Text] [Related]
13. Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis.
El-Osta H; Jafri S
Immunotherapy; 2019 Feb; 11(3):189-199. PubMed ID: 30730276
[TBL] [Abstract][Full Text] [Related]
14. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Liu T; Ding S; Dang J; Wang H; Chen J; Li G
J Thorac Dis; 2019 Jul; 11(7):2899-2912. PubMed ID: 31463119
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.
Wang S; Hao J; Wang H; Fang Y; Tan L
Oncoimmunology; 2018; 7(8):e1457600. PubMed ID: 30221052
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
Yang K; Li J; Bai C; Sun Z; Zhao L
Front Oncol; 2020; 10():1098. PubMed ID: 32733805
[No Abstract] [Full Text] [Related]
17. Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.
Huang Q; Zhang H; Hai J; Socinski MA; Lim E; Chen H; Stebbing J
Oncoimmunology; 2018; 7(12):e1396403. PubMed ID: 30524878
[No Abstract] [Full Text] [Related]
18. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Tan PS; Aguiar P; Haaland B; Lopes G
Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.
Liang H; Lin G; Wang W; Huang J; Yang Y; Lan Y; Wang R; Cui F; Hao Z; Deng H; Zhao S; Cheng B; Xiong S; Li J; Li C; Liu J; He J; Liang W
Transl Lung Cancer Res; 2020 Apr; 9(2):188-203. PubMed ID: 32420059
[TBL] [Abstract][Full Text] [Related]
20. Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials.
Facchinetti F; Di Maio M; Tiseo M
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
